InvestorsObserver
×
News Home

Where Does Wall Street Think Recursion Pharmaceuticals Inc (RXRX) Stock Will Go?

Friday, March 03, 2023 02:54 PM | InvestorsObserver Analysts

Mentioned in this article

Where Does Wall Street Think Recursion Pharmaceuticals Inc (RXRX) Stock Will Go?

Wall Street is positive on Recursion Pharmaceuticals Inc (RXRX). On average, analysts give RXRX a Buy rating. The average price target is $13.4, which means analysts expect the stock to increase by 57.28% over the next twelve months. That average ranking earns RXRX an Analyst Rating of 18, which is better than 18% of stocks based on data compiled by InvestorsObserver.

Overall Score - 3.4
Wall Street analysts are rating RXRX a Buy today. Find out what this means to you and get the rest of the rankings on RXRX!

Why are Analyst Ratings Important?

Fundamental research of the underlying health of a company can be an extremely useful resource when making investment decisions. Analysts observe growth prospects and forecasted earnings of companies to gain a comprehensive view of particular industries. This data allows traders to react before numbers are officially reported. InvestorsObserver takes the ratings from these analysts and percentile ranks those aveages. This allows you to compare stocks extensively and in more detail than the common buy/hold/sell ratings.

What's Happening With Recursion Pharmaceuticals Inc Stock Today?

Recursion Pharmaceuticals Inc (RXRX) stock is trading at $8.52 as of 2:54 PM on Friday, Mar 3, a gain of $0.51, or 6.37% from the previous closing price of $8.01. The stock has traded between $8.03 and $8.54 so far today. Volume today is low. So far 338,250 shares have traded compared to average volume of 885,144 shares. Click Here to get the full Stock Report for Recursion Pharmaceuticals Inc stock.

You May Also Like

Get the InvestorsObserver App

InvestorsObserver App
iOS App Android App